Research on the Applications of Big Data on Artistic Designing and Its Infl uences on the Design Behavior

In this paper, we conduct research on the applications of big data on artistic designing and its infl uences on the design behavior. Modern art design enhance the grade of the product, increase the added value of products, promote the development of the economy, make the product of the aesthetic value and economic value of the perfect unity. In today’s society due to the value of the product are much more than the product itself contains the value of performance, usage, etc. is more of a product in gradually improve the aesthetic value, sometimes even more than the use of the product value and exchange value, therefore the product has become the dominant value. Under this basis, we propose the new idea on the design pattern that will be meaningful.

An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma

No clinically available biomarkers can predict pathological complete response(pCR)for esophageal squamous cell carcinomas(ESCCs)with neoadjuvant chemoradiotherapy(nCRT).Considering that antitumor immunity status is an important determinant for nCRT,we performed an integrative analysis of immune-related gene profiles from pretreatment biopsies and constructed the first individualized immune signature for pCR and outcome prediction of ESCCs through a multicenter analysis.During the discovery phase,14 differentially expressed immune-related genes(DEIGs)with greater than a twofold change between pCRs and less than pCRs(<pCRs)were revealed from 28 pretreatment tumors in a Guangzhou cohort using microarray data.Ten DEIGs were verified by qPCR from 30 cases in a Beijing discovery cohort.Then,a four-gene-based immune signature(SERPINE1,MMP12,PLAUR,and EPS8)was built based on the verified DEIGs from 71 cases in a Beijing training cohort,and achieved a high accuracy with an area under the receiver operating characteristic curve(AUC)of 0.970.The signature was further validated in an internal validation cohort and an integrated external cohort(Zhengzhou and Anyang cohorts)with AUCs of 0.890 and 0.859,respectively.Importantly,a multivariate analysis showed that the signature was the only independent predictor for pCR.In addition,patients with high predictive scores showed significantly longer overall and relapse-free survival across multiple centers(P<0.05).This is the first,validated,and clinically applicable individualized immune signature of pCR and outcome prediction for ESCCs with nCRT.Further prospective validation may facilitate the combination of nCRT and immunotherapy.

The combination of novel immune checkpoints HHLA2 and ICOSLG:A new system to predict survival and immune features in esophageal squamous cell carcinoma

Studies on immune checkpoint inhibitors targeting B7-CD28 family pathways in esophageal squamous cell carcinoma(ESCC)have shown promising results.However,a comprehensive understanding of B7-CD28 family members in ESCC is still limited.This study aimed to construct a novel B7-CD28 family-based prognosis system to predict survival in patients with ESCC.We collected 179 cases from our previously published microarray data and 86 cases with qPCR data.Specifically,119 microarray data(GSE53624)were used as a training set,whereas the remaining 60 microarray data(GSE53622),all 179 microarray data(GSE53625)and an independent cohort with 86 qPCR data were used for validation.The underlying mechanism and immune landscape of the system were also explored using bioinformatics and immunofluorescence.We examined 13 well-defined B7-CD28 family members and identified 2 genes(ICSOLG and HHLA2)with the greatest prognostic value.A system based on the combination HHLA2 and ICOSLG(B7-CD28 signature)was constructed to distinguish patients as high-or low-risk of an unfavorable outcome,which was further confirmed as an independent prognostic factor.As expected,the signature was well validated in the entire cohort and in the independent cohort,as well as in different clinical subgroups.The signature was found to be closely related to immune-specific biological processes and pathways.Additionally,high-risk group samples demonstrated high infiltration of Tregs and fibroblasts and distinctive immune checkpoint panels.Collectively,we built the first,practical B7-CD28 signature for ESCC that could independently identify high-risk patients.Such information may help inform immunotherapy-based treatment decisions for patients with ESCC.